Phosphomannomutase 2 deficiency, or PMM2-CDG, is the most common congenital disorder of glycosylation affecting over 1,000 patients globally. There are no approved drugs that treat the symptoms or root cause of PMM2-CDG. In order to identify clinically actionable compounds that boost human PMM2 enzyme function, we performed a multi-species drug repurposing screen using a first-ever worm model of PMM2-CDG followed by PMM2 enzyme functional studies in PMM2-CDG patient fibroblasts.
Introduction
Deficiency of the enzyme phosphomannomutase-2 caused by loss-of-function mutations in the human PMM2 gene was shown over two decades ago to be the basis of a recessive congenital disorder of glycosylation originally called CDG1 or CDG1a. The first clinical observation by Jaeken and colleagues of a "carbohydrate-deficient glycoprotein syndrome" occurred four decades ago (Jaeken et al, 1980) . The researcher and patient communities now refer to the disease as PMM2-CDG, which is the most common congenital disorder of glycosylation affecting at least 1,000 patients worldwide (Chang et al, 2018) .
Classical pediatric clinical presentations include developmental delay, severe encephalopathy with axial hypotonia, abnormal eye movements, psychomotor retardation and cerebellar hypoplasia (Matthijs et al, 1997) . As patients reach their teenage years and young adulthood, health challenges include hypogonadism, coagulation abnormalities and thrombotic events, retinitis pigmentosa and peripheral neuropathy (Monin et al, 2014) The prognosis for PMM2-CDG patients is poor and there is currently no FDA approved treatment that alleviates the symptoms of PMM2-CDG or any targeted therapy that safely increases PMM2 enzyme activity.
The PMM2 enzyme forms an obligate homodimer in the cytoplasm that converts mannose-6-phosphate to mannose-1-phosphate, an initial essential step in the N-linked glycosylation of proteins. Glucose-1,6-bisphosphate and mannose-1,6-bisphosphate are endogenous coactivators of PMM2 function, binding to and stabilizing PMM2 dimers (Andreotti et al, 2015) . N-linked protein glycosylation is an evolutionarily In order to identify drug repurposing candidates that boost PMM2 enzyme function, we generated and characterized the first worm patient avatar of PMM2-CDG as an intermediate translational model situated between our previously published yeast models (Lao et al, 2019) and well-established PMM2-CDG patient fibroblasts. We created a viable hypomorphic loss-of-function F119L homozygous mutant worm for use in a primary in vivo phenotypic drug screen and a secondary in vitro worm PMM2 enzyme activity assay. We showed that this F119L hypomorphic mutant exhibits hypersensitivity to the proteasome inhibitor and ER stress inducer bortezomib, resulting in early larval arrest. Compounds that rescue arrested worm larvae and allow for normal development could activate ER stress response pathways to overcome chronic proteome-wide hypoglycosylation or boost PMM2 enzyme activity or boost PMM2 protein abundance. We adapted a low-throughput PMM2 enzymatic activity assay to a multi-well-plate assay using PMM2-CDG patient fibroblasts (Van Schaftingen & Jaeken, 1995) in order to determine which clinical candidates from model organism drug repurposing screens increase human PMM2 enzymatic activity.
The majority of repurposing candidates are "generally recognized as safe" plant-derived polyphenols, or phytochemicals, specifically a structurally-related group of antidiabetic and antioxidant dietary flavonoids. These flavonoids (e.gs., fisetin, ellagic acid) appear to share a common target and mechanism of action with a cinnamic acid derivative that specifically rescued a F119L yeast model of PMM2-CDG (Lao et al, 2019) , namely aldose reductase inhibition. Based on structure-activity relationships, we found that epalrestat, a generic diabetic peripheral neuropathy drug and the only safe aldose reductase inhibitor approved for use in humans (Hotta et al, 2006) , is a first-in-class PMM2 enzyme activator. The efficacy of epalrestat in four genotypically distinct PMM2-CDG fibroblasts tested in this study suggests that epalrestat could be given to PMM2-CDG patients who are compound heterozygous for R141H and any pathogenic variant. However, epalrestat treatment of PMM2-CDG fibroblasts did not increase PMM2 protein levels as measured by immunoblotting, suggesting that aldose reductase inhibition acts posttranslationally to boost PMM2 enzyme activity. We propose that aldose reductase inhibition leads to an increase in glucose-1,6-bisphosphate levels as a result of glucose being shunted away from the polyol pathway toward production of phosphorylated glucose. Evidence from epalrestat-treated pmm-2 mutant worms suggests there may also be a minor role for NRF2 as an indirect transcriptional activator of PMM2, which is consistent with a role for NRF2 activation in rescuing hypoglycosylation stress phenotypes a pmm2 mutant zebrafish (Mukaigasa et al, 2018) .
Epalrestat is an oral formulation of an aldose reductase inhibitor which has been commercially approved and available in Japan since 1992 for the treatment of diabetic neuropathies. It is also commercially available in India and China. The drug was never commercially approved in the United States or EU but it has a long and safe history. The drug's ability to safely improve symptoms of neuropathy alone by reducing oxidative stress, increasing glutathione levels, and reducing intracellular sorbitol accumulation make it a desirable medication for PMM2-CDG patients who commonly suffer with various neuropathies. Based on the data presented herein, the newly discovered PMM2 enzyme activation mechanism of epalrestat may reduce the severity of the morbidities associated with PMM2-CDG.
Materials and Methods

Strains, cell lines and compounds
The pmm-2 mutant VC3054 was obtained from the Caenorhabditis Genetics Center (CGC). It is a homozygous lethal deletion chromosome balanced by GFP-marked translocation. COP1626 is the pmm-2 F125L (F119L in humans) hypomorphic homozygous mutant that was generated using CRISPR/Cas9 by NemaMetrix, Inc. The R141H/F119L patient fibroblast line GM20942 was obtained from Coriell. The R141H/E139K patient fibroblast line GM27386 was obtained from Coriell. The R141H/N216I patient fibroblast line was obtained from the Mayo Clinic biobank. The R141H/F183S patient fibroblast line was obtained from the Mayo Clinic biobank. Control fibroblasts GM05757, GM08398, GM08429 were ordered from Coriell. Screening was conducted using the 2,560-compound Microsource Spectrum library consisting of FDA approved drugs, bioactive tool compounds, and natural products. For all retests, compounds were reordered from Spectrum Discovery as 5 milligram dry powder stocks. Compounds were solubilized with fresh dimethylsulfoxide (DMSO) at high concentrations of 100mM or 50mM and stored as aliquots at -20C. For worm retesting, a 10mM stock was prepared.
High-throughput larval growth assays in worms
The F125L/F125L homozygous pmm-2 mutant growth screen was conducted in 384-well plates. 320 wells of the plate are filled with 25μM of compound (137.5nL) from the Microsource Spectrum library, dispensed into each well of the plate using an Echo 550 acoustic dispenser from Labcyte, Inc. In addition, all test wells were dispensed with 12.5nL of a 50mM stock of bortezomib solubilized in DMSO, resulting in a final concentration of 11μM. Control wells of the plate were filled with 150nL of DMSO (positive control), or 12.5nL of bortezomib and 137.5nL of DMSO (negative control). Following addition of test compounds, wells were dispensed with 5μL of bacterial media resuspended in S-medium containing cholesterol after adjusting the optical density to 0.45 at 600nm. Mutant animals were grown on standard nematode growth media agar plates until gravid. Adult worms were bleached using hypochlorite treatment to obtain eggs. Eggs were allowed to hatch overnight at 20˚C in order to obtain synchronized L1 larvae. L1 larvae were filtered through 15-micron filters to ensure that the resulting population was clean before sorting. Fifteen L1 larvae are dispensed per well of the 384-well plate using a BioSorter large particle flow cytometer from Union Biometrica. Plates were sealed and incubated on a shaker at 20˚C for five days. On the fifth day, plates were vortexed and spun down before the addition of 15μL of 8mM sodium azide. The addition of sodium azide immobilized worms after which they were imaged under transmitted light using a custom plate imager. Finally, automated image processing was run on each plate.
Data analysis and statistical methods
We used the statistical program R to calculate Z-scores after processing the raw data, and we used Excel to calculate p values using t tests. We used custom image processing algorithms to extract areas occupied by worms per well. After outlier elimination among controls, i.e., elimination of data points on account of image or experimental artifacts, Z-scores were assigned to each well of the plate relative to the negative controls. Next, all wells that had a Z-score of greater than two in triplicate were isolated and manually inspected. Because bortezomib suppresses larval growth and induces arrest, we determined that a compound rescued the underlying defect if a well had a higher area occupied by worms relative to the negative control. Visual inspection often revealed that in primary screening positive wells, animals attained adulthood and produced progeny.
PMM2 enzymatic assay in worms
L1-stage-synchronized F125L/F125L homozygous pmm-2 mutant animals were grown (2,000 worms per plate) on NGM agar for 24 hours. After 24 hrs, worms were washed off plates into 15mL conical tubes, washed with filtered autoclaved water, pelleted at 3,200 rpm for 4 mins, and then resuspended in 2mL Smedium. HB101 bacteria grown in LB overnight was pelleted at 4,000 rpm for 10 minutes and resuspended in S-medium with cholesterol to an optical density of 0.35. For each experimental condition, 25mL of HB101 in S-medium was added to 50mL conical tubes along with 15,000 to 20,000 worms.
Test compounds were dissolved in DMSO stock solutions and added to samples at a final concentration of 15µM. Samples were incubated at 20˚C for 24 hours. After 24 hours, conical tubes were placed on ice, and worms were allowed to settle for 15 minutes. The bacterial supernatant was aspirated, and the worms were pelleted and washed with water. Worms were transferred to 1.5mL Eppendorf tubes, pelleted at 4˚C, and lysed in 70-100µL homogenization buffer (20mM Hepes, 25mM KCl, 1mM DTT, 10µg/mL leupeptin, 10µg/mL antipain) on ice. The lysate was centrifuged, and 1-2µL of lysate was used for protein quantification using a Qubit. Lysate equivalent of 10µg protein was used per well to determine PMM-2 enzyme activity levels after adding the 200µL of assay buffer. Assay buffer without the substrate was used as the control and the assay was carried out for 3-4 hours with absorbance readings every 30 minutes at 340nm.
PMM2 enzymatic assay development in R141H/F119L patient fibroblasts
Briefly, cells were seeded in a 96-well plate, homogenization buffer (20mM Hepes, 25mM KCl, 1mM
DTT, 10µg/mL leupeptin, 10µg/mL antipain) was added, and plates were freeze-thawed at -80˚C twice to lyse cells. Reaction buffer containing the substrate was then added to the wells of each plate. Plates were incubated at 37˚C for 30 minutes and absorbance was read at 340nm at regular time points: 30, 60, 90, 120, 150, 180, 210, 240 and 270 minutes. All incubations are carried out with or without substrate (mannose-1-phosphate), and the difference between the two values was taken as the enzymatic activity. Enzyme activity was normalized to total lysate protein levels. Enzyme activity of wildtype fibroblasts and patient-derived compound heterozygous (F119L/R141H) fibroblast line were determined.
To assess if compounds from the phenotypic screens affected enzyme activity, all compounds were incubated with the mutant cell line at a concentration of 10μM for a 24-hour period. Following this, enzyme activity was assessed as described above. At least two biological replicates were conducted and enzyme activity in the presence of a test compound was compared to DMSO-treated mutant cell line. For ease of analysis, we compared the enzyme activity (as represented by NADPH concentration) of each treatment condition to activity of baseline, untreated mutant line at the last time point.
Epalrestat treatments in optimized PMM2 enzymatic activity assay
Samples were lysed using sonication, after which total protein concentration was determined through Biorad LSR total protein detection assay. For each sample, 1.0 mg/mL protein wa used for further analysis. After lysis, samples were centrifuged at 10,000 rpm for 10 minutes. After centrifugation, 80 µL of supernatant was transferred to a microtiter plate. PMM2 substrate mannose 1-phosphate (Man1P) was added to each sample after which the plate was transferred to a FLUOstar Omega Plate Reader to determine fluorescent excitation after 30 and 40 minutes as a measure of PMM2 enzyme activity. All samples were run in duplicate with each run including healthy control and disease control standards.
Enzyme activity scores are presented as nmol/h/mg protein using the following formula:
Keap1-NRF2 activation luciferase reporter assay in U2OS cells
Hit compounds were tested by DiscoverX (San Diego) using the PathHunter® eXpress Keap1-NRF2 Nuclear Translocation Assay. Briefly, PathHunter cells are plated and incubated for 24 hours at 37°C. 10µL of test compound was added and cells were incubated with compound for 6 hours at room temperature. Working detection reagent solution was added and plates were incubated for 60 minutes at room temperature. Chemiluminescence signal was read by a SpectraMax M3. Methyl CDDO ester was used as the positive control. To be called a NRF2 activator, a hit compound had a half-maximal effective concentration (EC 50 ) less than 10µM and a slope comparable to methyl CDDO ester.
PMM2 protein quantification by immunoblotting in fibroblasts
To isolate protein, cells were washed in 1X PBS and pelleted. Cell pellets were solubilized in RIPA Buffer + Protein Inhibitor Cocktail. Protein concentration was determined using the BCA method.
Immunoblotting was performed as follows. 30µg cell protein was separated on a 10% Bis-Tris gel (NP0301PK2, ThermoFisher, Inc) and blotted onto nitrocellulose membranes using the standard protocol provided by the manufacturer. Rabbit polyclonal antibody against human PMM2 (10666-1-AP, Proteintech) was diluted 1/333 (30µL in 10mL blocking buffer). Mouse monoclonal antibody against human ACTB (AC004, CiteAb) was diluted 1:15,000 (0.66µL in 10mL blocking buffer). Membranes were blocked for 30 minutes at 4˚C in SEA Block blocking buffer (37527, ThermoFisher. Primary antibodies were diluted in 10mL SEA Block. Membranes were incubated on a rocker in primary antibody dilution overnight at 4˚C. Membranes were washed six times for 10 minutes in 40mL 1X PBS+ 0.1% Tween at room temperature. Donkey anti-mouse green (SA5-10172, ThermoFisher) and donkey antirabbit red (SA5-10042, ThermoFisher) fluorescent antibodies were diluted 1:5,000 (2µL each in 10mL blocking buffer). Membranes were incubated in secondary antibody dilution for one hour at 4˚C.
Membranes were then washed six times for 10 minutes in 40mL 1X PBS+ 0.1% Tween at room temperature. Finally, membranes were washed once for 10 minutes in 40mL 1X PBS at room temperature and immediately visualized.
Quantitative RT-PCR of worms
Worms were age-synchronized and collected as day 1 adults. Worm pellets were homogenized and RNA extracted following published protocols (Guthmueller et al, 2011) . ER stress markers were selected based on the pmm2 zebrafish model (Mukaigasa et al, 2018) . Cq stands for cycle quantification.
Results
Generation and phenotyping of the first nematode model of PMM2-CDG
We addressed the lack of animal models for PMM2-CDG that are amenable to unbiased high-throughput phenotypic screens by creating a series of worm patient avatars. The F52B11.6 gene sequence in C.
elegans is orthologous to human PMM2. Nematode PMM-2 shares 54% identity with the human protein, and the two most common disease-causing mutations --R141H and F119L --are evolutionarily conserved. We first characterized a heterozygous pmm-2 null strain. This strain has a 518-base-pair deletion in the PMM-2 open reading frame. This deletion strain is documented to be larval lethal, which we confirmed (data not shown). The heterozygous animals produce few homozygous null progeny, insufficient for the scale of a high-throughput drug screen. We used quantitative RT-PCR to measure the amount of worm PMM-2 mRNA expression in pmm-2 heterozygote null animals. We observed that worm PMM-2 mRNA levels are the same in wildtype N2 animals and pmm-2 heterozygote null animals, indicating that this mutant compensates for hemizygosity at the transcriptional level by boosting PMM-2 expression to levels normally expressed in wildtype worms with two functional copies of PMM-2 (Supplementary Figure 1) . Because pmm-2 homozygous nulls are inviable and pmm-2 heterozygous nulls do not exhibit overt growth and developmental delay phenotypes, we engineered a novel pmm-2 hypomorphic mutant strain using CRISPR/Cas9 and examined it for phenotypes amenable to a highthroughout image-based growth assay and a low-throughput whole-animal PMM2 enzyme activity assay.
We created a homozygous F125L/F125L missense mutant, as worm F125 is orthologous to human F119.
F119 sits in the dimer interface and the F119L mutation results in a defect in dimerization. The homozygous pmm-2 F125L (hereafter referred to as F119L) strain is homozygous viable and does not exhibit larval lethality, growth defects or any observable locomotor defects in liquid media. We verified that worm PMM-2 mRNA transcript levels in the F119L mutant are comparable to wildtype N2 animals (Supplementary Figure 1) . In order to determine if the F119L homozygote mutant is a bona fide model of PMM2-CDG, we measured worm PMM2 enzyme activity in F119L homozygotes after whole-animal lysis. As expected, this mutant has reduced PMM2 enzymatic activity, while by contrast PMM2 enzymatic activity is unchanged in a png-1 homozygous null mutant and model of NGLY1 Deficiency, another glycosylation disorder, and wildtype N2 worms (Figure 1 ).
Drug repurposing screen using pmm-2 F125L/F125L mutant worms
Because the F119L homozygous mutant strain presented no constitutive growth and developmental timing differences compared to wildtype worms, it was not amenable to high-throughput screening as is.
We tested if pmm-2 mutant animals are more sensitive to pharmacological stressors that disrupt proteasomal processes and induce ER stress. Literature evidence shows that tunicamycin (Buzzi et al, 2011 ) and bortezomib (Tillman et al, 2018) exposure causes proteasomal stress, activates the unfolded protein response and induces larval arrest in worms. We treated F119L mutant animals with increasing concentrations of tunicamycin and bortezomib. We sought to establish if either compound affected growth and development of mutant animals at concentrations lower than similarly exposed wildtype worms. Tunicamycin did not produce differential larval arrest in mutants and wildtype worms possibly because the F119L mutation is not sensitizing enough (data not shown). It is possible tunicamycin might produce a differential larval arrest in the context of modeling a more severe PMM2 variant in worms.
As shown in Figure 2 , we found that pmm-2 mutant worms exposed to bortezomib, a reversible proteasome inhibitor, displayed larval arrest at concentrations more than 10-fold lower than wildtype. At the highest concentration tested (13.6µM), F119L mutant worms uniformly arrested as small larvae with morphological defects or were dead, whereas wildtype worms at this dose were viable late-stage larvae or young adults ( Figure 1A) . Starting at 1.6µM bortezomib, the size distribution of pmm-2 mutant worms separates from the size distribution of wildtype worms. At concentrations higher than 6.8µM, pmm-2 mutant worms arrest as small sick larvae with no overlap between mutant and wildtype worm size distributions ( Figure 2B) . We decided to screen the Microsource Spectrum drug repurposing library in triplicate for compounds that rescue early larval arrest in the presence of 11μM bortezomib, a concentration which guaranteed robust statistical separation of positive control Z-scores (DMSO-treated pmm-2 mutant worms) from negative control Z-scores (bortezomib-treated pmm-2 mutant worms). We previously screened the Microsource Spectrum library using yeast models of PMM2-CDG (Lao et al, 2019) . We anticipated identifying overlapping chemotypes active in both species.
Representative positive control wells and negative control wells are shown in Figure 3 . Note that the worms in negative control wells are still viable even if they are arrested ( Figure 3B ). Statistically significant separation between positive and negative controls allowed us to identify both suppressors and enhancers, which include toxic compounds (Supplementary Figure 2) . We only examined suppressors in the context of this study, i.e., compounds that fully rescue early larval arrest induced by 11µM bortezomib. Note that the worms in wells containing suppressors look indistinguishable from worms in positive control wells (Fig. 3D versus Fig. 3B ). 20 compounds had Z-scores greater than five in all three replicates ( Figure 3A) , resulting in a suppressor hit rate of 0.781%, which is consistent with the hit rates we observed in previous whole-organism phenotypic drug repurposing screens in flies (Rodriguez et al, 2018 ) and yeast (Lao et al, 2019) . contains the tropolone core scaffold that is pyrogallin, are flavanols present in green and black teas. It is known that gossypetin can directly inactivate bortezomib, resulting in false positive hits so we removed it from further consideration (Glynn et al, 2015) .
The chemical structures of all twenty PMM2 repurposing candidates are shown in Figure 4 . Remarkably, our flavonoid repurposing candidates have all been reported to be aldose reductase inhibitors (ARI) in the single to low double digit µM concentration range, and therefore would display this activity under the conditions of the primary drug repurposing screen and secondary hit validation assays. Fisetin, quercetin tetramethylether and rhamnetin were shown to inhibit aldose reductase with half-maximal inhibitory concentrations of 3.7µM, 25µM and 2.7µM, respectively (Matsuda et al, 2002) . Quercetin was identified in 1975 as an aldose reductase inhibitor (Varma et al, 1975; Varma et al, 1977) .
The flavonoid 2'-2'-bisepigallocatechin digallate (Supplementary Figure 3) was identified as one of three repurposing candidates in our previously published yeast PMM2 drug repurposing study (Lao et al, 2019) , and is structurally related to theaflavin digallate. This result demonstrates that specific plant-based polyphenols rescue in both yeast and worm species paradigms by a conserved mechanism of action. Plantbased polyphenols also are all well-known antioxidants that activate cytoprotective responses like the Keap1-Nrf2 pathway, which is not conserved in yeast. We tested the 20 worm repurposing candidates in yeast PMM2-CDG models and in a human cell-based Keap1-Nrf2 activity assay.
Cross-species retesting of worm repurposing candidates in yeast and fibroblasts
We performed two secondary screens in order to prioritize the 20 worm repurposing candidates for final validation testing in PMM2-CDG patient fibroblasts in a human PMM2 enzyme activity assay representing the most common genotype R141H/F119L. First, we tested all 20 worm repurposing candidates in three genotypically distinct yeast PMM2-CDG models (Lao et al, 2019) . 10/20 (50%) of the worm repurposing candidates improved growth of one or more yeast PMM2 models (Figure 4;   Supplementary Figure 7) . Theaflavin monogallate, epicatechin monogallate and koparin and ethylnorepinephrine rescued two out of three yeast PMM2-CDG models but were not considered further.
Quercetin tetramethylether, amidol and dobutamine rescue growth in a dose-dependent manner in all three yeast PMM2-CDG models. Quercetin tetramethylether had the largest effect size, so we began to suspect that it acts as an aldose reductase inhibitor because aldose reductase is conserved in yeast.
It is possible that inactivity in the yeast PMM2-CDG models could be the result of compound insolubility or instability in yeast media versus in worm media, or other organism-specific assay variables. In order to dissect the polypharmacology of plant-based polyphenols, we tested all 20 worm repurposing candidates in a Keap1-Nrf2 reporter human cell assay. We reasoned that plant-based polyphenols are known antioxidants, and some have been reported to activate the transcriptional regulator NRF2. Compounds that scored positively in the Keap1-Nrf2 reporter assay were then tested in a PMM2 enzyme activity assay on PMM2-CDG R141H/F119L fibroblasts in order to triage the list of compounds down to one or a few most promising repurposing candidates. We optimized PMM2 enzymatic assays for worms and for patient fibroblasts based on the previously reported protocol (Van Schaftingen & Jaeken, 1995) .
When we tested all 20 worm repurposing hits in a Keap1-Nrf2 reporter assay in human cells, only 4/20 (20%) of the compounds activated NRF2: fisetin, rhamnetin, pyrogallin and purpurogallin-4-carboxylic acid (Figure 4) . Fisetin is a known NRF2 activator (Smirnova et al, 2011) . The other three were not previously known to activate NRF2. None of the four worm repurposing candidates that activate the Keap-Nrf2 reporter assay rescued any of the yeast PMM2-CDG models, which is the expected result given the lack of conservation of NRF2 in yeast. Pyrogallin, purpurogallin-4-carboxylic acid, rhamnetin and fisetin do not rescue any of the yeast PMM2-CDG models tested. In fact, all four inhibit growth of all three yeast PMM2-CDG yeast models tested, with pyrogallin and purpurogallin-4-carboxylic acid having larger effect sizes than fisetin and rhamnetin (Supplementary Figure 7) .
Validating aldose reductase inhibitors in PMM2 enzymatic assays in worms and fibroblasts
Next, we tested the four worm repurposing candidates that activated the Keap1-Nrf2 pathway in a human PMM2 enzymatic activity assay using a R141H/F119L PMM2-CDG patient fibroblast line. We also Figure 3) . 15µM CHCA increased worm PMM2 enzymatic activity by 50% over baseline but the variance is large so the result is not statistically significant (p = 0.4175). Similarly, 10µM
CHCA increased human PMM2 enzymatic activity by 40% and is marginally statistically significant because of the variance (p = 0.0436) as shown in Figure 5B . The worm repurposing candidates pyrogallin, purpurogallin-4-carboxylic acid and fisetin activated human PMM2 enzymatic in PMM2-CDG R141H/F119L fibroblasts (Figure 4 ) but they inhibit all three yeast PMM2-CDG models at all three concentrations tested. Therefore, we deprioritized those three compounds and focused on CHCA because it had the largest effect size in terms of increasing PMM2 enzymatic activity.
CHCA is a potent aldose reductase inhibitor (Zhang et al, 2016) , which is consistent with the known ARI mechanism of action of dietary flavonoids. The predominant ARI pharmacophore contains a terminal carboxylic acid moiety like CHCA. We reasoned that the variance associated with CHCA may be due to its relative pharmacological promiscuity and off-target effects. Therefore, we tested the following nine commercially available aldose reductase inhibitors (ARIs) representing the known ARI pharmacophores, including those containing the terminal carboxylic acid moiety shared with CHCA: tolrestat, ranirestat, imirestat, zopolrestat, sorbinil, ponalrestat, alrestatin, fiderastat and epalrestat. Tolrestat, imirestat, ponalrestat and alrestatin increased PMM2 enzymatic activity in only one of three replicates (data not shown).
Of the ARIs tested, only carboxylic acid-containing epalrestat and CHCA reproducibly increased PMM2 enzymatic activity in both worms ( Figure 5A ) and fibroblasts ( Figure 5B) . In pmm-2 F119L mutant worms, 15µM epalrestat treatment caused a 30% increase in PMM2 enzymatic activity (p = 0.0352) . In R141H/F119L PMM2-CDG fibroblasts, 10µM epalrestat also caused a 30% increase in PMM2 enzymatic activity over baseline (p = 0.00825). Epalrestat happens to be the only ARI that is orally bioavailable, brainpenetrant, well-tolerated and approved for use in humans. Epalrestat was approved for the treatment of diabetic neuropathy in geriatric patients in Japan in 1992 (Hotta et al, 1996) , and is also available in China and India, but has not been approved by the Food and Drug Adminstration (FDA) for any indications. In light of all these data, we deprioritized CHCA, which is not approved for use in humans, in favor of the safe and generic epalrestat that has been used for decades in Asia.
Epalrestat boosts PMM2 enzyme activity in multiple PMM2-CDG patient fibroblasts
We tested whether the ARI epalrestat increases human PMM2 enzymatic activity in more than one PMM2 genotype and genetic background. Even though the compound heterozygous genotype R141H/F119L is the most common genotype observed in PMM2-CDG patients worldwide, there is a long tail of private missense mutations in trans with R141H so we tested three additional genotypes: R141H/E139K, R141H/N216I and R141H/F183S. Incubation of human PMM2-CDG derived fibroblasts with 10µM epalrestat for 24 hours led to an increase in PMM2 enzymatic activity in all tested samples ( Figure 6 ). As summarized in Table 1 , each PMM2-CDG fibroblast line has a different PMM2 enzymatic activity baseline, reflecting the severity of the respective PMM2 mutations correlating with enzyme activity impairment.
Patient R141H/E139K fibroblasts show the lowest un-supplemented PMM2 enzyme activity but attain the largest relative increase in PMM2 enzyme activity levels after 24 hours of epalrestat treatment: 4.06-fold increase from 18 to 72 nmol/h/mg. Patient R141H/N216I fibroblasts have the highest PMM2 enzyme activity baseline and attain the smallest relative increase in PMM2 enzyme activity levels with epalrestat: 1.39-fold increase from 67 to 93 nmol/h/mg. Patient R141H/F183S fibroblasts show robust rescue in epalrestat: 3.15-fold increase from 34 to 107 nmol/h/mg. Averaging across the three genotypes, PMM2 activity increases 2.29-fold over the vehicle-treated baseline (p = 0.0321). Supplemented PMM2 activity levels did not reach the formal patient control reference activity value of >700 nmol/h/mg, yet the identification of several-fold increased PMM2 activity by 10µM epalrestat in 24 hours represents a proofof-concept for the therapeutic application of epalrestat in remediation of loss of PMM2 enzymatic activity.
Epalrestat does not increase PMM2 protein abundance
The simplest model to explain how epalrestat increases PMM2 enzyme activity levels is that epalrestat increases PMM2 protein abundance. We demonstrated previously that PMM2 overexpression rescues lethality of yeast models of PMM2-CDG by mass action effects (Lao et al, 2019) . The results of immunoblotting with antibody specific to PMM2 clearly show that epalrestat treatment does not increase PMM2 protein abundance in PMM2-CDG fibroblasts or in control fibroblasts ( Figure 7A ).
In two out of three PMM2-CDG fibroblasts, the PMM2 protein abundance increases upon epalrestat treatment, but in the third PMM2-CDG fibroblast PMM2 protein abundance decreases upon epalrestat treatment; and we observed the reverse trend in three control fibroblasts ( Figure 7B ). We averaged PMM2 protein abundance fold change in epalrestat-treated PMM2-CDG fibroblasts and then compared it to the averaged PMM2 protein abundance fold change in control fibroblasts ( Figure 7C ). There is no statistically significant difference. Furthermore, we observed a weak positive trend between baseline PMM2 protein abundance versus baseline PMM2 enzyme activity ( Figure 7D) . Together, these results clearly demonstrate that the increase in PMM2 enzyme activity levels is not explained by increased PMM2 protein abundance. The increase in PMM2 enzyme activity levels must therefore be explained by increased catalysis of each PMM2 homodimer already present in the cell, not an increase in the total cellular concentration of PMM2 protein via transcriptional upregulation of PMM2 mRNA.
Epalrestat increases PMM2 mRNA expression and rescues ER stress markers in worms
It was recently reported that a pmm2 hypomorphic mutant zebrafish constitutively activates NRF2 and furthermore that the small molecule NRF2 activator sulforaphane ameliorates endoplasmic reticulum (ER)-associated stress markers (Mukaigasa et al, 2018 ). Therefore, we tested whether epalrestat acts similarly to sulforaphane by interrogating mRNA expression levels of the worm orthologs of the ER stress markers that are induced in a pmm2 hypomorphic mutant zebrafish. The results of this qPCR analysis are shown in Supplemental Figure 5 . PMM-2 transcript levels are increased by 15µM epalrestat. Transcript levels of HSP-1, which encodes a heat shock protein, are also increased by epalrestat treatment. Conversely, the ER stress markers IRE-1, PEK-1, SKN-1, and GCS-1, which are constitutively elevated in the F119L mutant, are modestly decreased by treatment with epalrestat. These results bolster confidence in the translational fidelity of our F119L worm model of PMM2-CDG because it phenocopies the constitutively active ER stress response seen in a zebrafish model of PMM2-CDG.
Discussion
We set out in this study to build on the results of our previous yeast PMM2-CDG disease modeling and drug repurposing efforts (Lao et al, 2019) . We filled a gap in PMM2-CDG disease models by generating a nematode model based on a specific PMM2-CDG variant, in this case the second-most common missense allele F119L (F125L in worms). We confirmed that the F119L nematode model has between 30-40% residual PMM-2 enzymatic activity, comparable to a haploid F119L yeast model. We identified hypersensitivity to the proteasome inhibitor bortezomib as a growth-based phenotype in an unbiased whole-organism drug repurposing screen. A comparative analysis of yeast and worm PMM2 repurposing hits revealed overlap in one structural class: plant-based polyphenols. Using a PMM2 enzymatic activity assay in PMM2-CDG patient fibroblasts, we showed that several yeast and worm repurposing candidates increase PMM2 enzymatic activity. These compounds are the first known small molecule activators of PMM2 enzymatic activity.
Analysis of structure-activity relationships and cross-species testing suggested that plant-based polyphenols are acting as aldose reductase inhibitors (ARIs). Upon testing commercially available ARIs, we showed conclusively that epalrestat boosts PMM2 enzymatic activity in both nematodes and PMM2-CDG patient fibroblasts. Epalrestat is the only ARI approved for the treatment of diabetic neuropathy in humans and has been used safely for nearly three decades. It has been used to treat peripheral neuropathy in geriatric diabetic patients in Asia for several decades. We believe our results justify repurposing epalrestat for PMM2-CDG, starting with a small safety and efficacy study involving up to ten PMM2-CDG patients. The only other example of drug repurposing for PMM2-CDG involves the carbonic anhydrase inhibitor acetazolamide, and the therapeutic thesis is that acetazolamide will treat the cerebellar syndrome of PMM2-CDG but not correct the root cause of disease which is PMM2 enzyme insufficiency (Martinez-Monseny et al, 2019) .
What is the mechanism of action by which epalrestat potentiates PMM2 enzymatic activity? We initially hypothesized that activation of NRF2 would lead to increased PMM2 mRNA levels, which in turn would lead to increased PMM2 protein abundance. Consistent with that hypothesis, treatment of pmm2 zebrafish mutant with the NRF2 activator sulforaphane resulted in rescue of phenotypic defects (Mukaigasa et al, 2018) . We know from our studies of yeast PMM2-CDG models that overexpression of F119L mutant PMM2 protein can rescue growth by mass action effects (Lao et al, 2019) . Four plantbased polyphenols -fisetin, rhamnetin, pyrogallin and purpurogallin-4-carboxylic acid -are active in the Keap1-Nrf2 cellular reporter assay, but only two of them -fisetin and pyrogallin -boost PMM2 enzymatic activity. Several reports indicate that epalrestat activates NRF2 in cultured cells (Yama et al, 2016; Yama et al, 2015) . Using quantitative RT-PCR, we showed that epalrestat treatment of pmm-2 F125L/F125L homozygote worms modestly upregulates SKN-1 transcripts. SKN-1 is the worm ortholog of NRF2. As a direct test of this model, we quantified PMM2 protein abundance in PMM2-CDG patient fibroblasts by immunoblotting. Epalrestat does not increase PMM2 protein abundance in any of the fibroblast lines tested.
Therefore, we favor a model where epalrestat acts post-translationally to boost PMM2 enzymatic activity by preventing glucose from being shunted down the polyol pathway. Aldose reductase is the first biosynthetic enzyme in the polyol pathway, and ARIs block the conversion of glucose to sorbitol. Excess glucose would then favor the production of glucose-1,6-bisphosphate, an endogenous small molecule coactivator of PMM2 (Pirard et al, 1999; Monticelli et al, 2019) . At the same time, inhibition of the polyol pathway reduces the levels of advanced glycation end products, which would attenuate the sequelae of ER stress and oxidative stress. In humans, epalrestat is known to reduce the levels of carboxymethyl lysine, a known advanced glycation end product (Kawai et al, 2010) . It is also possible that there is a complex interaction between activation of NRF2 and inhibition of the polyol pathway, the former acting at the transcriptional level and the latter acting post-translationally.
Our model make several testable predictions. First, the concentration of glucose-1,6-bisphosphate will increase in yeast, worms and human cells treated with epalrestat. Second, the concentration of sorbitol will decrease in yeast, worms and human cells treated with epalrestat. Third, CRISPR knockout of aldose reductase in PMM2-CDG patient fibroblasts will block epalrestat's activation of PMM2 enzyme activity.
In the interim, decades of safe and effective administration of epalrestat in geriatric populations for peripheral neuropathy suggests that the drug may also be safe in pediatric settings necessitated by PMM2-CDG. Peripheral neuropathy is observed in almost all PMM2-CDG patients, so a therapeutic rationale for repurposing epalrestat for PMM2-CDG is compelling.
There are over 180 publications on the use of epalrestat in the past 25 years in the peer-reviewed literature. Epalrestat has been studied in three pivotal registration studies, and multiple post market studies have been conducted. The drug has an excellent safety profile, with the most common side effects reported being nausea, vomiting, diarrhea, and elevated liver enzymes, and the most severe side effect reported being liver failure. Will the PMM2 enzyme activity level increases in epalrestat-treated patient fibroblasts lead to clinical benefit in patients? The expectation is that epalrestat will treat the peripheral neuropathy of PMM2-CDG patients but will it have impact beyond peripheral neuropathy? Based on Mayo Clinic's PMM2-CDG biobank, 55 affected fibroblast lines exhibit a range of PMM2 enzymatic activity between 18-307 nmol/hr/mg. Mayo Clinic uses a diagnostic cutoff at 307 nmol/hr/mg. 66 unrelated non-carrier control fibroblast lines exhibit a range of PMM2 enzymatic activity between 712-2066 nmol/hr/mg. Mayo Clinic reports as healthy PMM2 enzymatic activity as any value > 712 nmol/hr/mg. It is believed by clinicians working on PMM2-CDG that > 100 nmol/hr/mg of PMM2 enzymatic activity would translate to clinical benefit. : 1nM, 14nM, 23nM, 45nM, 91nM, 230nM, 450nM, 1.6µM, 2.3µM, 6.8µM, 13.6µM . Z-score labels on the y-axis are 0, -4, -8 and -12.
Individual black dots represent statistical outliers. 
